COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,722 Articles (22,502 medRxiv, 8,220 bioRxiv)

Most recent first Previous |  Page 1668: Articles 16671-16680  | Next

Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis
The COVID-19 Host Genetics Initiative, , ganna, a.
10.1101/2021.03.10.21252820 — Posted: 2021-03-12
The impact of headache disorders on COVID-19 survival: a world population-based analysis
Shapiro, R. E., Gallardo, V. J., Caronna, E., Pozo-Rosich, P.
10.1101/2021.03.10.21253280 — Posted: 2021-03-12
Spread and sources of information and misinformation about COVID-19 early during the pandemic in a U.S. national cohort study
Westmoreland, D. A., Berry, A., Zimba, R., Kulkarni, S. G., Parcesepe, A., Maroko, A. R., Poehlein, E., You, W., Mirzayi, C., Kochhar, S., Robertson, M., Waldron, L., Grov, C., Nash, D.
10.1101/2021.03.10.21252851 — Posted: 2021-03-12
Repeated Testing Necessary: Assessing Negative Predictive Value of SARS-CoV-2 qPCR in a Population of Young Adults
Thompson, E. E., Rosenthal, J. H., Wren, J., Seetao, E., Olson, N. H.
10.1101/2021.03.10.21253292 — Posted: 2021-03-12
Disulfiram associated with lower risk of Covid-19: a retrospective cohort study
Fillmore, N., Bell, S., Shen, C., Nguyen, V., La, J., Dubreuil, M., Strymish, J., Brophy, M., Mehta, G., Wu, H., Lieberman, J., Do, N., Sander, C.
10.1101/2021.03.10.21253331 — Posted: 2021-03-12 Discussion: Onsite
Bayesian inference across multiple models suggests a strong increase in lethality of COVID-19 in late 2020 in the UK
Pietzonka, P., Brorson, E., Bankes, W., Cates, M. E., Jack, R. L., Adhikari, R.
10.1101/2021.03.10.21253311 — Posted: 2021-03-12
The BioNTech / Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization
Lixenfeld, A. S., Kuensting, i., Martin, E. L., von Kopylow, V., Lehrian, S., Lunding, H. B., Buhre, J. S., Quack, J. L., Steinhaus, M., Graf, T., Ehlers, M., Rahmoeller, J.
10.1101/2021.03.10.21252001 — Posted: 2021-03-12
Wastewater Surveillance of SARS-CoV-2 across 40 U.S. states
Wu, F., Xiao, A., Zhang, J., Moniz, K., Endo, N., Armas:, F., Bushman, M., Chai, P. R., Duvallet, C., Erickson, T. B., Foppe, K., Ghaeli, N., Gu, X., Hanage, W. P., Huang, K. H., Lee, W. L., Matus, M., McElroy, K. A., Rhode, S. F., Wuertz, S., Thompson, J., Alm, E. J.
10.1101/2021.03.10.21253235 — Posted: 2021-03-12 Discussion: Offsite
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
Dite, G. S., Murphy, N. M., Allman, R.
10.1101/2021.03.09.21253237 — Posted: 2021-03-12
Kinetics and seroprevalence of SARS-CoV-2 antibodies - a comparison of 3 different assays
Kahre, E., Galow, L., Unrath, M., Haag, L., Blankenburg, J., Dalpke, A., Lueck, C., Berner, R., Armann, J. P.
10.1101/2021.03.10.21253273 — Posted: 2021-03-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).